154 related articles for article (PubMed ID: 33048115)
41. The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in
Wu DW; Lin PL; Wang L; Huang CC; Lee H
Theranostics; 2017; 7(5):1114-1132. PubMed ID: 28435452
[TBL] [Abstract][Full Text] [Related]
42. CRISPR/Cas9: a powerful tool in colorectal cancer research.
Hu Y; Liu L; Jiang Q; Fang W; Chen Y; Hong Y; Zhai X
J Exp Clin Cancer Res; 2023 Nov; 42(1):308. PubMed ID: 37993945
[TBL] [Abstract][Full Text] [Related]
43. Effect of Cetuximab-Conjugated Gold Nanoparticles on the Cytotoxicity and Phenotypic Evolution of Colorectal Cancer Cells.
El Hallal R; Lyu N; Wang Y
Molecules; 2021 Jan; 26(3):. PubMed ID: 33499047
[TBL] [Abstract][Full Text] [Related]
44. CircIFNGR2 enhances proliferation and migration of CRC and induces cetuximab resistance by indirectly targeting KRAS via sponging to MiR-30b.
Zhang Q; Zheng Y; Liu J; Tang X; Wang Y; Li X; Li H; Zhou X; Tang S; Tang Y; Wang X; He H; Li T
Cell Death Dis; 2023 Jan; 14(1):24. PubMed ID: 36639711
[TBL] [Abstract][Full Text] [Related]
45. Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.
Borrero-Palacios A; Cebrián A; Gómez Del Pulgar MT; García-Carbonero R; Garcia-Alfonso P; Aranda E; Elez E; López-López R; Cervantes A; Valladares M; Nadal C; Viéitez JM; Guillén-Ponce C; Rodríguez J; Hernández I; García JL; Vega-Bravo R; Puime-Otin A; Martínez-Useros J; Del Puerto-Nevado L; Rincón R; Rodríguez-Remírez M; Rojo F; García-Foncillas J
Sci Rep; 2019 Feb; 9(1):2589. PubMed ID: 30796344
[TBL] [Abstract][Full Text] [Related]
46. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
47. Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance.
Tak E; Kim M; Cho Y; Choi S; Kim J; Han B; Kim HD; Jang CS; Kim JE; Hong YS; Kim SY; Kim TW
Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34779495
[TBL] [Abstract][Full Text] [Related]
48. A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations.
Chen D; Huang X; Cai J; Guo S; Qian W; Wery JP; Li QX
Oncotarget; 2015 Dec; 6(38):40815-21. PubMed ID: 26512781
[TBL] [Abstract][Full Text] [Related]
49. Platycodin D represses β-catenin to suppress metastasis of cetuximab-treated KRAS wild-type colorectal cancer cells.
Lv Y; Wang W; Liu Y; Yi B; Chu T; Feng Z; Liu J; Wan X; Wang Y
Clin Exp Metastasis; 2023 Aug; 40(4):339-356. PubMed ID: 37326719
[TBL] [Abstract][Full Text] [Related]
50. HER2
Gharib E; Salmanipour R; Nazemalhosseini Mojarad E; Yaghoob Taleghani M; Sarlak S; Malekzade-Moghani M; Nasrabadi PN; Meiary MA; Asadzadeh Aghdaei H; Zali MR
J Cell Physiol; 2019 Aug; 234(8):13137-13144. PubMed ID: 30549033
[TBL] [Abstract][Full Text] [Related]
51. Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer.
Arai H; Millstein J; Loupakis F; Stintzing S; Wang J; Battaglin F; Kawanishi N; Jayachandran P; Soni S; Zhang W; Mumenthaler SM; Cremolini C; Heinemann V; Falcone A; Lenz HJ
Eur J Cancer; 2021 Jun; 150():133-142. PubMed ID: 33901792
[TBL] [Abstract][Full Text] [Related]
52. EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer.
Okada Y; Kimura T; Nakagawa T; Okamoto K; Fukuya A; Goji T; Fujimoto S; Sogabe M; Miyamoto H; Muguruma N; Tsuji Y; Okahisa T; Takayama T
Mol Cancer Res; 2017 Oct; 15(10):1445-1454. PubMed ID: 28698359
[TBL] [Abstract][Full Text] [Related]
53. HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.
Takegawa N; Yonesaka K; Sakai K; Ueda H; Watanabe S; Nonagase Y; Okuno T; Takeda M; Maenishi O; Tsurutani J; Satoh T; Okamoto I; Nishio K; Tamura T; Nakagawa K
Oncotarget; 2016 Jan; 7(3):3453-60. PubMed ID: 26657506
[TBL] [Abstract][Full Text] [Related]
54.
Xu JM; Wang Y; Wang YL; Wang Y; Liu T; Ni M; Li MS; Lin L; Ge FJ; Gong C; Gu JY; Jia R; Wang HF; Chen YL; Liu RR; Zhao CH; Tan ZL; Jin Y; Zhu YP; Ogino S; Qian ZR
Clin Cancer Res; 2017 Aug; 23(16):4602-4616. PubMed ID: 28424201
[No Abstract] [Full Text] [Related]
55. Paxillin is positively correlated with the clinicopathological factors of colorectal cancer, and knockdown of Paxillin improves sensitivity to cetuximab in colorectal cancer cells.
Du C; Wang X; Zhang J; Liu X; Zhu J; Liu Y
Oncol Rep; 2016 Jan; 35(1):409-17. PubMed ID: 26530439
[TBL] [Abstract][Full Text] [Related]
56. Effect of cetuximab combined with chemotherapy in treating metastatic colorectal cancer and its prognostic analysis.
Wu J; Wang Z; Jin C; Ren H; Hu Y; Yang B; Hu Y
J BUON; 2021; 26(1):101-108. PubMed ID: 33721439
[TBL] [Abstract][Full Text] [Related]
57. Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients.
Bray SM; Lee J; Kim ST; Hur JY; Ebert PJ; Calley JN; Wulur IH; Gopalappa T; Wong SS; Qian HR; Ting JC; Liu J; Willard MD; Novosiadly RD; Park YS; Park JO; Lim HY; Kang WK; Aggarwal A; Kim HC; Reinhard C
Sci Rep; 2019 Oct; 9(1):15365. PubMed ID: 31653970
[TBL] [Abstract][Full Text] [Related]
58. ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.
Geißler AL; Geißler M; Kottmann D; Lutz L; Fichter CD; Fritsch R; Weddeling B; Makowiec F; Werner M; Lassmann S
Oncotarget; 2017 Mar; 8(10):17164-17190. PubMed ID: 28199979
[TBL] [Abstract][Full Text] [Related]
59. PUM1 Is Overexpressed in Colon Cancer Cells With Acquired Resistance to Cetuximab.
Liu Q; Xin C; Chen Y; Yang J; Chen Y; Zhang W; Ye L
Front Cell Dev Biol; 2021; 9():696558. PubMed ID: 34447749
[TBL] [Abstract][Full Text] [Related]
60. Disease Modeling on Tumor Organoids Implicates AURKA as a Therapeutic Target in Liver Metastatic Colorectal Cancer.
Boos SL; Loevenich LP; Vosberg S; Engleitner T; Öllinger R; Kumbrink J; Rokavec M; Michl M; Greif PA; Jung A; Hermeking H; Neumann J; Kirchner T; Rad R; Jung P
Cell Mol Gastroenterol Hepatol; 2022; 13(2):517-540. PubMed ID: 34700030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
